TAK-881
Sponsors
Takeda Development Center Americas Inc., Takeda
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)Healthy VolunteersPrimary Immunodeficiency DiseasesPrimary Immunodeficiency Diseases (PID)Primary Immunodeficiency Diseases (PIDD)
Phase 1
A Study of TAK-881 in Healthy Adults
CompletedNCT05059977
Start: 2021-10-12End: 2022-04-12Updated: 2024-01-12
A Study of TAK-881 and HyQvia in Healthy Adults
CompletedNCT06895967
Start: 2025-03-24End: 2025-07-24Updated: 2025-08-19
A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults
CompletedNCT06935266
Start: 2025-04-22End: 2025-09-22Updated: 2025-11-03
Phase 2
A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases
CompletedNCT05755035
Start: 2023-10-24End: 2026-01-20Updated: 2026-02-03
Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in Primary Immunodeficiency Diseases (PIDD)
Active, not recruitingCTIS2022-502095-23-01
Start: 2024-09-10Target: 27Updated: 2026-01-27
Phase 3
A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases
RecruitingNCT06076642
Start: 2024-11-04End: 2029-01-15Target: 39Updated: 2025-05-08
Long-term Safety and Tolerability of TAK-881 in Subjects with Primary Immunodeficiency Diseases (PIDD)
RecruitingCTIS2023-505946-24-00
Start: 2025-05-15Target: 19Updated: 2026-01-27
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
RecruitingNCT06747351
Start: 2025-05-06End: 2028-06-25Target: 59Updated: 2026-01-20
A Phase 3, Single-Arm, Multiple-Dose, Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
RecruitingCTIS2024-517450-95-00
Start: 2025-06-23Target: 46Updated: 2025-12-01